We bring to your attention a new website where you can buy propecia australia at a low price with fast delivery to Australia.
Commission de l’énergie
NOTICE OF APPLICATION AND WRITTEN HEARING
Exelon Generation Company, LLC
Application for an Electricity Wholesaler Licence Renewal
Exelon Generation Company, LLC has applied to the Ontario Energy Board for
renewal of their electricity wholesaler licence. The granting of this licence would
enable the applicant to wholesale electricity in Ontario.
The application will be decided by an employee of the Board who has been
delegated this authority pursuant to section 6 of the Ontario Energy Board Act,
. The employee does not intend to provide for an award of costs when
Copies of the application and the pre-filed evidence in support of the applicant’s
application will be available for public inspection at the Board’s offices, or at the
How to Participate in the Hearing
The Board intends to proceed with this matter by way of a written hearing unless a
party satisfies the Board that there is a good reason for not holding a written
hearing. If you object to the Board holding a written hearing in this matter, you
must provide written reasons why an oral hearing is necessary. Any submissions
objecting to a written hearing must be received by the Board and copied to the
If you wish to participate in the written hearing, please file a written submission
setting out your views on the application. You must forward two paper copies, and
if possible, an electronic copy in Word format and in searchable PDF format, of
your submission to the Board and one copy to the applicant at the addresses
below. All submissions must be received by November 30, 2011. If the applicant
wishes to respond to the submissions, such response must be filed with the Board
and copied to any party that made submissions by December 7, 2011.
All submissions must quote the relevant file number, and clearly state the sender’s
name, postal address, telephone number, fax number and e-mail address. All
communications should be directed to the attention of the Board Secretary at the
address below, and be received no later than 4:45 p.m. on the required date.
All written submissions sent to the Board will be placed on the public record, which
means that the written submissions will be available for viewing at the Board's
offices and will be placed on the Board's website.
If the written submission is from a private citizen (i.e., not a lawyer representing a
client, not a consultant representing a client or organization, not an individual in an
organization that represents the interests of consumers or other groups, and not
an individual from a regulated entity), before placing the written submission on the
public record, the Board will remove any personal (i.e., not business) contact
information from the written submission (i.e., the address, fax number, phone
number, and e-mail address of the individual). However, the name of the
individual and the content of the written submission will become part of the public
As stated elsewhere in this notice, you must provide a complete copy of your
written submission (including your name, contact information, and everything
written in the submission) to the applicant.
Information relating to the application is available for viewing at the Board’s offices
at the address provided below or by contacting the applicant. The address and
contact information for the applicant are also provided below.
Further information on how to participate may be obtained by visiting the Board’s
IF YOU DO NOT FILE AN OBJECTION TO A WRITTEN HEARING OR DO NOT
PARTICIPATE IN THE HEARING BY FILING A SUBMISSION IN ACCORDANCE
WITH THIS NOTICE, THE BOARD MAY PROCEED WITHOUT YOUR
PARTICIPATION AND YOU WILL NOT BE ENTITLED TO FURTHER NOTICE IN
at Toronto, November 4, 2011 ONTARIO ENERGY BOARD
Original Signed By
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) December 2000 Additional copies are available from: Office of Training and Communications Division of Communications Management (Internet) http://www.fda.gov/cder/guidance/index.htm Office of Communication
Tamoxifen Therapy for Breast Cancer and Endometrial Cancer Risk Leslie Bernstein, Dennis Deapen, James R. Cerhan, Stephen M. Schwartz,Jonathan Liff, Erin McGann-Maloney, Jeffrey A. Perlman, Leslie Ford cancer risk was at least as great as that of a 60-year-old woman Background: Tamoxifen is effective in treating breast cancer, to receive either tamoxifen (20 mg/day for 5 years) or plac